Actually, the proportion of lung cancer patients with the driver mutations is relatively small, for instance, EGFR mutations account for 10–15% of NSCLC7, ALK rearrangements account for 2–5%, and ROS1 fusions occur in 1–4%.2 Here, ALK is linked to lung cancer.